Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
about
Transmitted drug resistance in persons with acute/early HIV-1 in San Francisco, 2002-2009A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu miceStructure-based design, synthesis and validation of CD4-mimetic small molecule inhibitors of HIV-1 entry: conversion of a viral entry agonist to an antagonist.Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applicationsMultiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development.The host interactome of influenza virus presents new potential targets for antiviral drugs.Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data.Assessment of the pharmacokinetics of co-administered maraviroc and raltegravirOral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor.Binding mode characterization of NBD series CD4-mimetic HIV-1 entry inhibitors by X-ray structure and resistance study.Antiretroviral therapy in macrophages: implication for HIV eradication.Antiviral drugs specific for coronaviruses in preclinical developmentNew treatments for influenzaDesign, synthesis and biological evaluation of novel piperazine derivatives as CCR5 antagonists.The genotypic false positive rate determined by V3 population sequencing can predict the burden of HIV-1 CXCR4-using species detected by pyrosequencing.A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanismsInteractions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors.Clinical use of CCR5 inhibitors in HIV and beyondNon-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc.Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaquesBiophysical characterization of small molecule antiviral-loaded nanolipogels for HIV-1 chemoprophylaxis and topical mucosal application.Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.Macaque studies of vaccine and microbicide combinations for preventing HIV-1 sexual transmission.Anti-α4 Integrin Antibody Blocks Monocyte/Macrophage Traffic to the Heart and Decreases Cardiac Pathology in a SIV Infection Model of AIDS.Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women.Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.Targeting chemokine receptors in disease--a case study of CCR4Past, present and future molecular diagnosis and characterization of human immunodeficiency virus infections.Identification of dual-tropic HIV-1 using evolved neural networks.Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.CCR6 is required for IL-23-induced psoriasis-like inflammation in mice.Modeling HIV persistence, the latent reservoir, and viral blips.Synthesis, docking, and biological studies of phenanthrene β-diketo acids as novel HIV-1 integrase inhibitors.Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors.The impact of pharmacogenetics on HIV therapy.Chemokine receptor antagonists: Part 1.
P2860
Q28476489-D48C7108-413E-4FE6-9BA0-D3CA6D9EB3E5Q28478394-65668741-9081-485E-BF60-ECD1A4F6A82EQ30358736-E293F8F2-2517-4DD4-8C94-BFE55D54DA09Q30366071-ABDE3F81-587B-4808-8371-C55D481EA8FDQ30381745-15C1520D-BA5A-4BD4-B4C7-32C9A29CD086Q30405769-010B86E2-C467-4359-8965-7D9D30AE3DF5Q30564042-A2C56E69-95FE-41FA-B46E-9C95B15C899FQ33696575-D16301DE-7082-4324-A77F-0D6E924F95D5Q33784852-28F42EFE-1D09-45EC-87CB-03A0BA8C879DQ34047706-6785ABC3-46AF-4B55-B693-B993A4FC4B6CQ34057606-13ED78C1-2386-4005-A29E-192FD90E5446Q34298792-27859AD7-AD96-46C3-836B-9CCFF2C30083Q34332580-59D91F95-3BBC-42FC-AEDA-57D822A3A2C0Q34413797-39AB219C-1231-4330-A248-F3E48D8EF7EBQ34545281-17C647C8-531D-4385-A4B5-8632579451C0Q34558508-A21199DF-2AB9-403A-A8A1-A1E166AA57B9Q34606129-19AB37C5-759F-426C-BCDD-DAA9F9C24884Q34725136-DF1BB010-8F1D-4CBF-BF1B-FFAC032FD2E6Q35007339-37D13876-507E-449E-AF18-78E01EF86749Q35018145-E248177B-F302-4A43-A714-17B4DCDAC59AQ35563416-188FBC8E-9576-40DF-BED1-AD088CC72CA5Q35941408-AF1C3A00-5ABB-4327-BECB-8543A7AF317FQ35947035-124E1DCC-8A42-4820-977A-884ECA577722Q35968753-3AAFF7A0-49E2-46B9-AF53-6FB0D98D9B99Q36001347-DADEE735-E9B5-4D84-9CC1-8B538EFDFE8EQ36168754-9B82CE03-7542-45C3-ACE8-2A57372A30FEQ36187641-E1DAF77D-E908-4CAE-8EB1-9F2F0BFDB4F8Q36667196-680D4C7E-330E-42A2-A49E-F455D26BF3FFQ36669046-575E1817-1286-4033-A4B5-629BF84B8A38Q36779718-7E461A75-7F51-4982-8910-C0011FD5E7FEQ37038403-5D13766E-5DCA-4658-97A4-ECC2A7F64788Q37246452-1EA3A8A0-14B9-42F6-A162-39615AE2CCE7Q37256312-2D7AEB37-9CC6-4B32-8C50-BE78D2A498D3Q37271640-09425B40-8D39-4BD7-8AFA-232134A9A002Q37286597-D9705FDA-09E2-4436-B7A7-CAF7E8163C28Q37365718-D50E8C60-2BE5-44BB-A07A-3F7AD4F99E89Q37399113-3608B002-69FF-4A7B-86BF-4BF1DDA76780Q37399117-D195B5A5-FC0B-4F60-A935-9347C4A90273Q37405140-5944535A-53FA-457A-935F-ACFBDDC03387Q37481238-ACBCE56F-6240-4C09-B55B-C5246768B211
P2860
Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@ast
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@en
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@nl
type
label
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@ast
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@en
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@nl
prefLabel
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@ast
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@en
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@nl
P356
P1476
Reviews of anti-infective agen ...... lass of antiretroviral agents.
@en
P2093
Richard M Novak
Rodger D MacArthur
P304
P356
10.1086/589289
P407
P577
2008-07-01T00:00:00Z